CollPlant Biotechnologies Ltd

CollPlant Biotechnologies Ltd

CollPlant Biotechnologies was founded in 2004 and is headquartered in Ness Ziona, Israel. The company specializes in regenerative medicine, using genetically engineered tobacco plants to produce recombinant human collagen that serves as the base for 3D bioprinted tissues. This approach replaces traditional animal-derived collagen with a scalable, plant-based alternative. The company's primary focus is developing tissue-engineering products for orthopedics, wound healing, and soft tissue reconstruction. CollPlant's flagship technology, rhCollagen, is used in 3D bioinks for printing human tissues and organ scaffolds. In 2022, CollPlant entered a partnership with United Therapeutics to 3D print human lungs for transplant. The company also collaborates with medical device firms to develop resorbable implants and scaffold products for surgical applications. CollPlant is publicly traded on the Tel Aviv Stock Exchange and the Nasdaq, raising capital through public offerings rather than private family-office structures. The company's team includes scientists, engineers, and regulatory specialists. Its intellectual property portfolio covers 20+ patent families related to collagen production and 3D bioprinting methods. A structural differentiator is CollPlant's integration of plant molecular farming with additive manufacturing. The company controls the full production chain — from tobacco cultivation to protein extraction to ink formulation — a vertical model rare in biotech. This architecture eliminates reliance on animal supply chains and allows real-time customization of tissue geometries through 3D printing.